Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer
Randomized Phase II Study of Amrubicin as Single Agent or in Combination With Cisplatin Versus Etoposide-cisplatin as First-line Treatment in Patients With Extensive Stage SCLC (ES)
研究概览
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
-
Genova、意大利、16132
- Instituto Nazionale per la Ricerca sul Cancro
-
Udine、意大利、33100
- Università degli Studi di Udine
-
-
-
-
-
Antwerpen、比利时、2020
- Algemeen Ziekenhuis Middelheim
-
Edegem、比利时、2650
- Universitair Ziekenhuis Antwerpen
-
Gent、比利时、9000
- Universiteit Gent
-
Leuven、比利时、3000
- U.Z. Gasthuisberg
-
Liege、比利时、4000
- Centre Hospitalier Regional de la Citadelle
-
Liege、比利时、1BE
- Domaine Universitaire Du SART-TILMAN
-
Namur、比利时、5000
- Clinique Sainte Elisabeth
-
-
-
-
-
Gdansk、波兰、80211
- Medical University of Gdansk - Dept Radiotherapy
-
-
-
-
-
Belfast、英国、BT9 7AB
- Belfast City Hospital
-
Edinburgh、英国、EH4 2XU
- Western General Hospital
-
Hull、英国、HU8 9HE
- Princess Royal Hospital
-
London、英国、SM2 5PT
- Royal Marsden Hospital, London
-
Manchester、英国、M20 4BX
- Christie Hospital
-
Newcastle-Upon-Tyne、英国、NE4 6BE
- Sir Bobby Robson Cancer Trials Research Centre
-
Sutton、英国、(Surrey) SM2 5PT
- Royal Marsden Hospital Lung Unit
-
-
Merseyside
-
Bebington、Merseyside、英国、CH684JY
- Clatterbridge Centre for Oncology NHS Trust
-
-
Scotland
-
Dundee、Scotland、英国、D01 9SY
- University of Dundee - Ninewells Hospital
-
-
-
-
-
Amsterdam、荷兰、1105 AZ
- Academisch Medisch Centrum
-
Amsterdam、荷兰
- The Netherlands Cancer Institute Antoni Van Leeuwenhoekziekenhuis
-
Enschede、荷兰、7500 KA
- Medisch Spectrum Twente - Dept of Pulmonary Diseases
-
Leiden、荷兰、2300RC
- Leiden University Medical Centre
-
Maastricht、荷兰、6202
- Academisch Ziekenhuis Maastricht
-
Zwolle、荷兰、8001
- Isala Kliniek
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Histologically/cytologically proven small cell lung cancer
- Extensive disease
- Measurable disease
- World Health Organization (WHO) performance status 0-2
- Age 18 years or older
- Normal baseline cardiac function
- No prior systemic chemotherapy for small cell lung cancer
- Adequate organ function including bone marrow, kidney, and liver
- No history of interstitial lung disease or pulmonary fibrosis
- No history of prior malignancy unless patient has been disease free for greater than 5 years, or the tumour was a non-melanoma skin cancer or in-situ carcinoma of the cervix
- No pregnancy or breast feeding; patients of child-bearing potential must agree to use an appropriate method of contraception
- Written informed consent before randomization
Exclusion criteria:
- Pre-existing peripheral neuropathy (greater than Grade 1, CTCAE version 3.0)
- Uncontrolled or severe cardiovascular disease
- Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Amrubicin
Amrubicin 45mg/m<2> IV days 1, 2, 3 of each 21-day cycle until disease progression.
|
Amrubicin 45mg/m<2> IV days 1, 2 3 of each 21-day cycle until disease progression. Amrubicin 40mg/m<2> IV days 1, 2, 3 plus cisplatin 60mg/m<2> day 1 of each 21-day cycle until disease progression. |
实验性的:Amrubicin plus Cisplatin
Amrubicin 40mg/m<2> IV days 1, 2, 3 plus cisplatin 60mg/m<2> IV day 1 of each 21-day cycle until disease progression.
|
Amrubicin 45mg/m<2> IV days 1, 2 3 of each 21-day cycle until disease progression. Amrubicin 40mg/m<2> IV days 1, 2, 3 plus cisplatin 60mg/m<2> day 1 of each 21-day cycle until disease progression. Amrubicin 40mg/m<2> IV days 1, 2, 3 plus Cisplatin 60mg/m<2> day 1 of each 21-day cycle until disease progression. Cisplatin 75mg/m<2> IV day 1 plus etoposide 100mg/m<2> IV day 1 and 200mg/m<2> orally days 2, 3 or etoposide 100mg/m<2> IV days 1, 2, 3 of each 21-day cycle until disease progression. |
有源比较器:Cisplatin plus etoposide
Cisplatin 75mg/m<2> IV day 1 plus etoposide 100mg/m<2> IV day 1 and 200mg/m<2> orally days 2, 3 or etoposide 100mg/m<2> IV days 1, 2, 3 each 21-day cycle until disease progression.
|
Amrubicin 40mg/m<2> IV days 1, 2, 3 plus Cisplatin 60mg/m<2> day 1 of each 21-day cycle until disease progression. Cisplatin 75mg/m<2> IV day 1 plus etoposide 100mg/m<2> IV day 1 and 200mg/m<2> orally days 2, 3 or etoposide 100mg/m<2> IV days 1, 2, 3 of each 21-day cycle until disease progression.
Cisplatin 75mg/m<2> IV day 1 plus etoposide 100mg/m<2> IV day 1 and 200mg/m<2> orally days 2, 3 or etoposide 100mg/m<2> IV days 1, 2, 3 of each 21-day cycle until disease progression.
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
Objective tumor response rate according to RECIST criteria measured every 2 cycles (every 6 weeks)
大体时间:Until Disease Progression
|
Until Disease Progression
|
次要结果测量
结果测量 |
大体时间 |
---|---|
总生存期
大体时间:直到死亡
|
直到死亡
|
Toxicity
大体时间:Until 30 days after last protocol treatment
|
Until 30 days after last protocol treatment
|
Progression-free survival
大体时间:Until disease progression or death
|
Until disease progression or death
|
合作者和调查者
赞助
调查人员
- 首席研究员:Mary O'Brien, MD、Royal Marsden Hospital, London, UK
出版物和有用的链接
一般刊物
- O'Brien ME, Konopa K, Lorigan P, Bosquee L, Marshall E, Bustin F, Margerit S, Fink C, Stigt JA, Dingemans AM, Hasan B, Van Meerbeeck J, Baas P. Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062. Eur J Cancer. 2011 Oct;47(15):2322-30. doi: 10.1016/j.ejca.2011.05.020. Epub 2011 Jun 16.
- Liddell RP, Evans NS. May-Thurner syndrome. Vasc Med. 2018 Oct;23(5):493-496. doi: 10.1177/1358863X18794276. No abstract available.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.